Anova Innovation Limited
EA Policies for Single Patient
Since no expanded access program (EAP) has been initiated for QLS4131 for the treatment of multiple myeloma patients in the US, according to company policy, Anova Innovation Limited encourages all potentially eligible patients to be considered for enrollment in the clinical study.
For more information, please refer to our company website for more information:https://en.qilupharma.com/news_details/10.html